Shield Therapeutics shares surge 21% as ACCRUFeR revenues double

Shield Therapeutics PLC shares surged 21% following a robust Q2 trading update, as net revenues for its iron deficiency treatment, ACCRUFeR, doubled to $12.8 million from $6.4 million in Q1, driven by increased prescriptions and a higher average net selling price. The company reported $10.8 million in cash and cash equivalents, with CEO Anders Lundstrom reiterating confidence in achieving positive cash flow by the end of 2025. Analysts, including Cavendish and Peel Hunt, expressed reassurance regarding the company's execution and maintained positive outlooks and price targets, valuing the business at £44 million.

Analysis

Shield Therapeutics PLC (AIM:STX) experienced a significant 21% share price increase driven by a robust second-quarter trading update that demonstrated strong commercial momentum. Net revenues for its key iron deficiency treatment, ACCRUFeR, doubled sequentially to $12.8 million from $6.4 million in Q1. This top-line growth was fueled by both an increase in prescription volume to approximately 47,000 and a notable improvement in the average net selling price, which rose from $187 to $231. The company's financial position appears stable with $10.8 million in cash and equivalents, supported by external milestone payments. Critically, management's reiterated guidance of achieving positive cash flow by the end of 2025 provides a clear forward-looking catalyst. This positive operational performance was endorsed by analysts, with Cavendish calling the execution "highly reassuring" and reiterating a 23p price target, while Peel Hunt issued a 'buy' recommendation, highlighting the new management's effectiveness.

Key Decisions for Investors

• The strong acceleration in ACCRUFeR revenue and pricing power signals significant commercial momentum, supporting a bullish thesis for investors focused on growth in the biotech sector.
• Investors should closely monitor the company's progress toward its stated goal of achieving cash flow positivity by the end of 2025, as meeting this target is a critical de-risking event for the business.
• Despite the recent share price surge, the current price of 4.29p remains substantially below analyst price targets of 15p and 23p, suggesting potential for further upside if the company continues to execute its plan effectively.